Early diagnosis in ATTRv amyloidosis, how early is enough? How early is possible?
Med Clin (Barc)
; 162(12): e70-e73, 2024 06 28.
Article
de En, Es
| MEDLINE
| ID: mdl-38614903
ABSTRACT
Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare, progressive, and debilitating genetic disorder characterized by the deposition of abnormal transthyretin (TTR) protein aggregates in various tissues, leading to organ dysfunction. Early diagnosis of ATTRv amyloidosis is critical for starting timely interventions and improving patient outcomes. This review explores the concepts of "how early is enough" and "how early is possible" in the context of diagnosing ATTRv amyloidosis, highlighting the challenges and opportunities for early recognition.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Préalbumine
/
Neuropathies amyloïdes familiales
/
Diagnostic précoce
Limites:
Humans
Langue:
En
/
Es
Journal:
Med Clin (Barc)
/
Med. clin (Ed. impr.)
/
Medicina clinica (Ed. impresa)
Année:
2024
Type de document:
Article
Pays de publication:
Espagne